

## Introduction:

Although sudden death is the most common cause of death in hemodialysis patients, the primary causes are uncertain.

•We recently reported that modifiable dialysis factors such as exposure to low potassium and calcium dialysate, as well as predialysis serum potassium and creatinine and are strong predictors of peridialytic in-clinic sudden cardiac arrest (SCA)<sup>1</sup>.

•Whether or not these factors are also predictive of sudden deaths occuring outside the dialysis clinic is unknown.

Study objective: To compare risk factors for in-clinic SCA and out-of-clinic sudden cardiac death (SCD).


## **Methods:**

- Patient Population: 43,200 prevalent hemodialysis patients dialyzing in 565 clinics of DaVita Inc. (formerly Gambro) in the United States between 2002-2005.
- Study Design: Nested Case-Control. We previously identified 502 patients who had a witnessed in-clinic SCA. Each SCA case patient with 3 random control patients matched by age, dialysis vintage, and year of event. The method employed by the USRDS CVSCC<sup>2</sup> was used to identify control patients who experienced sudden cardiac death outside of dialysis clinics.
- Data Source: Clinical Event Reporting database (ERMS) to adjudicate in-clinic SCA events. Laboratory data, comorbid conditions extracted from clinical database and linkage to USRDS.
- Study Design/Statistical Analysis:
- Data from 64,400 dialysis treatments compared between cohorts
- Repeated measures summarized over 90 day period leading up to event
- Multivariate logistic regression models used in adjusted analysis.

## Case-Mix and Reported Co-morbid Eactors

Case-Mix and Reported Co-morbid Factors					Dialysis Characteristics and Predialysis Lab Data					Prescribed Medications and Related Laboratory Data					
Variable	In-Clinic SCA	Out of Clinic SCD	No SCD	P value	Variable	In-Clinic SCA	Out of Clinic SCD	No SCD	P value	Variable	In-Clinic SCA	Out of Clinic SCD	No SCD	P value	
Median Age (years)	65	69	66	<0.001	Dialysis dose (urea reduction ratio)	0.72	0.71	0.71	0.8	% Beta-Blocker	58%	48%	49%	0.003	
Median Dialysis Vintage	2.9	2.9	2.7	0.3	Serum Potassium (meq/L)	4.72	4.66	4.78	0.07	% ACEI/ARB	57%	46%	44%	<0.0001	
(years) % Male	53%	55%	52%	0.7	% Last Treatment using Dialysate [K] < 2 meq/L	17.7%	10.1%	9.2%	<0.0001	% Statin	36%	23%	29%	0.001	
% White	47%	47%	42%	0.2	Serum Calcium (mg/dL)	9.26	9.20	9.17	0.4	% Aspirin	42%	48%	33%	<0.0001	
	-1770	7770	72 70	0.2		9.20	9.20	3.17	0.4	% Anti-arrhythmic	13%	20%	13%	<0.0001	
% Coronary Artery Disease	36%	47%	31%	<0.0001	% Last Treatment using Dialysate [Ca] < 2.5 meq/L	11.8%	6.6%	6.1%	<0.001	Serum Phosphorus	5.26	5.21	5.26	0.5	
% Congestive Heart Failure	40%	43%	34%	<0.0001	Ultrafiltration rate (cc/kg/min) (median over 90days)	10.4	10.0	10.1	0.5	(mg/dL) PTH (pg/mL)	218	216	225	0.2	
% History of Arrhythmia	14%	14%	13%	<0.001	Mean Arterial BP (mmHg)	98	96	102	<0.0001	% Vitamin D	78%	64%	72%	<0.001	
% Diabetes	57%	59%	53%	0.1	(predialysis, mean over 90 days)			Hemoglobin (g/dL)	11.5	11.6	11.7	<0.0001			
% Hypertension	87%	91%	87%	0.3	Serum Creatinine (mg/dL)	7.4	7.2	8.3	<0.0001		11.0	11.0	11.7	<0.0001	
% Hyperlipidemia	8%	7%	6%	0.4	Dialysis catheter access (%)	33%	33%	33%	0.9	EPO dose (U/treatment)	10543	7609	8752	<0.0001	
	070	170	070	0.4	Serum Albumin (mg/dL)	3.57	3.56	3.65	<0.0001						
% Peripheral Vascular Disease	21%	30%	18%	0.4	Serum Bicarbonate (meq/L)	21.3	22.2	21.5	<0.01						
% Cerebrovascular Disease	13%	12%	9%	0.3	Table 2: Comparison of independent Risk Factors Figure 2: Adjusted OR of Out-of-clinic SCD										
% Tobacco Use	3%	2%	4%	0.4	determined from multivariable logistic regression*										

### Figure 1: Study Design



**Duke**Medicine


# Risk Factors for Out-of-Clinic Sudden Cardiac Death in **Hemodialysis Patients**


Patrick H. Pun, MD, MHS; Ruediger W. Lehrich, MD; John P. Middleton, MD Department of Medicine, Division of Nephrology, Duke University Medical Center - Durham, North Carolina, USA

# **Results**

## **Table 1: Baseline Characteristics of the Study Cohorts**

## Dialysis Characteristics and Predialysis I ab Data





\*Variables entered into the model included all variables significantly associated with outcome in unadjusted analyses. Independent variables were confirmed by modeling using forward selection.

Error bars illustrate 95% CI. OR for EPO dose reported per increment of 1000U and MAP per increment of 10 mmHg

# **Clinical Research**

## Prescribed Medications and Related Laboratory Data



## Summary:

- Rate of in-clinic SCA was 7 per 1000 pt yrs.
- Rate of out-of-clinic SCD was 41 per 1000 pt yrs.
- Risk of both in-clinic and outof-clinic SCA was elevated in elderly patients, those with prior history of heart disease and those with lower blood pressure and biomarkers of poor nutrition.
- In-clinic SCA was associated with hemodialysis-related exposures such as low dialysate potassium and calcium
- In contrast, out of clinic SCD was higher among those with pre-existing CAD and those prescribed ASA, but lower in those treated with statin.

## **Conclusion:**

Changes to the hemodialysis prescription may reduce the rate of in-clinic SCA, but more conventional management of cardiovascular risk may be needed to reduce the greater risk of out-of-clinic SCA.

## **References:**

. Pun, PH et. al. Kidney Int. 2010 Sep 1. 2. USRDS Annual Data Report, 2006.

## **Acknowledgement:**

We thank DaVita Clinical Research (DCR) and the USRDS for providing the clinical data for this research project.

> **Correspondence:** Patrick.Pun@duke.edu